MARKET

LPTX

LPTX

LEAP THERAPEUTIC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.370
+0.140
+6.28%
After Hours: 2.370 0 0.00% 19:43 05/29 EDT
OPEN
2.200
PREV CLOSE
2.230
HIGH
2.480
LOW
2.200
VOLUME
649.04K
TURNOVER
--
52 WEEK HIGH
3.180
52 WEEK LOW
0.5728
MARKET CAP
84.84M
P/E (TTM)
-1.5055
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LPTX stock price target is 5.38 with a high estimate of 8.00 and a low estimate of 2.500.

EPS

LPTX News

More
HC Wainwright & Co. Reiterates Buy on Leap Therapeutics, Raises Price Target to $5
HC Wainwright & Co. reiterates Leap Therapeutics (NASDAQ:LPTX) with a Buy and raises the price target from $2.5 to $5.
Benzinga · 05/19 11:03
Analyst Estimates: Here's What Brokers Think Of Leap Therapeutics, Inc. (NASDAQ:LPTX) After Its First-Quarter Report
Simply Wall St. · 05/16 15:23
Leap Therapeutics Reports First Quarter 2020 Financial Results
PR Newswire · 05/14 12:00
Leap Therapeutics Q1 EPS $(0.550) Down From $(0.470) YoY, Sales $375.000K
Leap Therapeutics (NASDAQ:LPTX) reported quarterly losses of $(0.550) per share. This is a 17.02 percent decrease over losses of $(0.470) per share from the same period last year. The company reported $375.000 thousand
Benzinga · 05/14 11:10
Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination In Gynecologic Cancers
PR Newswire · 04/23 12:00
Leap Therapeutics Highlights Will Present Updated Data For DKN-01 Monotherapy, Paclitaxel Combo In Gynecologic Cancers
Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced updated clinical data from its ongoing Phase 2 clinical trial of DKN-01, its
Benzinga · 04/23 11:03
One Thing To Remember About The Leap Therapeutics, Inc. (NASDAQ:LPTX) Share Price
Simply Wall St. · 04/07 17:25
Leap Therapeutics Announces Executive Leadership Changes
PR Newswire · 03/18 12:00

Industry

Biotechnology & Medical Research
+1.44%
Pharmaceuticals & Medical Research
+1.29%

Hot Stocks

Symbol
Price
%Change

About LPTX

Leap Therapeutics, Inc. is a biopharmaceutical company developing therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. The Company’s programs are monoclonal antibodies that target key cellular pathways that enable cancer to grow and spread and specific mechanisms that activate the body’s immune system to identify and attack cancer. DKN-01 and TRX518 are its clinical stage programs. DKN-01 is a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). GITR is a receptor found on the surface of a wide range of immune cells.
More

Webull offers kinds of Leap Therapeutics Inc stock information, including NASDAQ:LPTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LPTX stock news, and many more online research tools to help you make informed decisions.